AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05744037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: regimen with BTK inhibitor +Anti-CD19 CAR T cells
Description: After FC regimen (fludarabine (25mg/m2/d) on days -5 to -3 and cyclophosphamide (750mg/m2) on days -5) were pretreated, Anti-CD19 CAR T cells were transfused on day 0. The dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. Intravenous drip/push at a constant rate for 30 minutes; Ibrutinib, a BTK inhibitor, was enrolled with a standard dose of 560mg qd.
Study NCT06371729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DEEP mapping
Description: The Substrate-based DEEP Mapping aims to identify the arrhythmogenic substrate of VT in sinus rhythm (SR). A standardized VT mapping and ablation procedure in SR has been proven effective in reducing VT recurrences in a multicenter setting by targeting late potential (LP) abolition. Regions with LPs and LAVAs that displayed decremental behavior evoked during right ventricular (RV) pacing with extra stimuli (decrement-evoked potential; DEEP), colocalized with the regions of the initiation and diastolic pathway of the VT more accurately than those areas displaying non decremental LPs.~Device use for mapping and ablation procedure:~FlexAbility/Tactiflex/TactiCath Ablation Catheter Sensor Enabled (Abbott, MN), high-density grid mapping catheter (GMC; Advisor HD Grid Mapping Catheter Sensor Enabled, Abbott, MN)
Study NCT06371729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Activation Mapping
Description: VT Activation Mapping can localize reentry circuits, and the diastolic pathway isthmus is the desirable target for ablation when possible because it can eliminate the elements required for reentry. In fact, activation mapping of the entire diastolic pathway is associated with higher freedom from VT recurrences compared to substrate modification~Device use for mapping and ablation procedure:~FlexAbility/Tactiflex/TactiCath Ablation Catheter Sensor Enabled (Abbott, MN), high-density grid mapping catheter (GMC; Advisor HD Grid Mapping Catheter Sensor Enabled, Abbott, MN)
Study NCT06441032 — intervention group
Intervention type: OTHER
Intervention: No patient treatment is associated with the study
Description: No patient treatment is associated with the study.
Study NCT05109637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Konectom NMD Application
Description: Administered as specified in the treatment arm.
Study NCT06287866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pinch Graft
Description: In the pinch graft technique, the investigators will numb and then shave off a thin piece of skin and place it in the wound bed.
Study NCT04319627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin Calcium
Description: Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
Study NCT04319627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
Study NCT04902313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Awareness and insight Modules (AiM)
Description: 12 week of daily reflection and meditation exercises, delivered by mobile phone text messages, after 3-4 live introduction sessions.
Study NCT04902313 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Awareness and insight Modules (AiM)
Description: 12 week of daily reflection and meditation exercises, delivered by mobile phone text messages, after 3-4 live introduction sessions.
Study NCT04429204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of tissue
Study NCT04429204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Undergo cryoablation
Study NCT05693493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proprioceptive knee brace
Description: For the intervention group that randomly consisted of 15 subjects will be using a design of knee brace (Reaction Web®; DonJoy, Vista, CA). The elastomeric web design helps to reduce pain by dispersing load across the knee. The web acts like a spring to absorb shock and shifts the peak loads away from the painful area of the knee. Elastomeric web acts to dynamically stabilise the patella on all sides, bringing the patella into proper tracking position to reduce pain for patients with general patellofemoral instabilities. Reaction Web® has dual-axis hinges that are flexible, creating synergy with the elastomeric web for optimal fit and support, and providing energy dispersion to the knee.
Study NCT06338293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran sodium
Description: The patients in Inclisiran group were given drugs three times in total. The first needle was injected subcutaneously with 284mg(1.5ml solution) after entering the group, the second needle was injected three months later and the third needle was injected at the ninth month.
Study NCT06338293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin
Study NCT03984019 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac condition measurements
Description: Cardiac MRI, ECG, echocardiography, cardiac blood markers
Study NCT04555512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive High Intensity Interval Training (PRO-HIIT)
Description: Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves progression of training of 3 stages: 1) six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min; 2) three high-intensity intervals of 2-min separated by two low-intensity intervals of 4-min, and a further 2-min of low intensity following the last interval before cool-down; and 3) three high-intensity intervals of 3-min separated by two low-intensity intervals of 3-min, and a further 1-min of low intensity following last interval before cool-down.
Study NCT04555512 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constant High Intensity Interval Training (CON-HIIT)
Description: Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves a constant protocol of training, including six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min.
Study NCT06338293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin
Study NCT04403958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRC
Description: Total wrist arthrodesis with dorsal plate using proximal row of the wrist as bone graft
Study NCT04403958 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TWA
Description: Total wrist arthrodesis with dorsal plate using iliac crest as bone graft
Study NCT05694975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: The total dosage of vitamin C for the treatment group is 24 g per day.
Study NCT05694975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The total dosage of placebo(5% glucose) for the control group is 24 g per day.
Study NCT04386590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy Plus Pulmonary Rehabilitation
Description: Manual therapy combined with Pulmonary Rehabilitation
Study NCT04386590 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Detuned US plus Pulmonary Rehabilitation
Study NCT05108584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPE Level 3 and Video Laryngoscope
Description: The operator used level 3 PPE and video laryngoscope for the intubation process
Study NCT05108584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPE Level 3 and Direct Laryngoscope
Description: The operator used level 3 PPE and direct laryngoscope for the intubation process
Study NCT05108584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPE Level 2 and Direct Laryngoscope
Description: The operator used level 2 PPE and direct laryngoscope for the intubation process
Study NCT05653271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting agent
Study NCT05653271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting agent
Study NCT05653271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE1831
Description: Allogeneic gamma delta T (gdT) cell therapy
Study NCT05653271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Anti-CD20 monoclonal antibody
Study NCT05657275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CRP dosage
Description: multimodal algorithm
Study NCT05657275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: multiplex PCR
Description: multimodal algorithm
Study NCT05657275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: chest scan without injection
Description: multimodal algorithm
Study NCT05288777 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: T-DM1
Description: Dosed at 3.6 mg/kg of body weight every 3 weeks for Her2/neu+ patients for a total duration of 14 cycles.
Study NCT05288777 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Dosed at 825 mg/m2 +/- 150mg twice per day for a total duration of 6 months
Study NCT05288777 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: External Beam Radiation Therapy 0
Description: Dose of 40 Gy in 15 fractions to the whole breast or chest wall followed by consideration of a 10 Gy in 4 fraction boost to the lumpectomy cavity for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
Study NCT05288777 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: External Beam Radiation Therapy 1
Description: Dose of 40 Gy in 15 fractions to either the breast or chest wall along with comprehensive nodal radiation followed by consideration of a 10 Gy in 4 fraction boost for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
Study NCT05182970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Individualised target dose of 2000 mg daily depending on tolerability.
Study NCT06152523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab/MEDI5257
Description: Phase II trial using an A'Hern design with a safety lead-in cohort to assess the safety/tolerability of the combination of monalizumab and MEDI5752 in patients with metastatic MSI/dMMR cancer
Study NCT05622890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
Study NCT05624086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Hepatitis-C Men With Sexual Dysfunction (erectile dysfunction) Complaint will receive exercise-training sessions (one hour walking on treadmill, for 3 months, three walking sessions per the week)
Study NCT04947826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC (Hepatic arterial infusion chemotherapy)
Description: For the HAIC procedure, a 5F catheter was introduced using the Seldinger technique through the femoral artery or the radial artery. Then, angiographic surveys of the celiac trunk and superior mesenteric artery were performed. According to tumor size, location, and arterial supply, the catheter or a 2.7F microcatheter was advanced into the hepatic artery at the level of selective segmental, lobar, or whole liver. The catheter or microcatheter was connected to an external infusion pump. The following regimen of modified FOLFOX was administered: oxaliplatin, 85mg/m2 for 2 hours; leucovorin, 400mg/m2; and 5-fluorouracil, 2400mg/m2 for 44-46 hours. After HAIC treatment, the catheter or microcatheter, and the sheath were removed.
Study NCT04947826 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: HAIC (Hepatic arterial infusion chemotherapy)
Description: For the HAIC procedure, a 5F catheter was introduced using the Seldinger technique through the femoral artery or the radial artery. Then, angiographic surveys of the celiac trunk and superior mesenteric artery were performed. According to tumor size, location, and arterial supply, the catheter or a 2.7F microcatheter was advanced into the hepatic artery at the level of selective segmental, lobar, or whole liver. The catheter or microcatheter was connected to an external infusion pump. The following regimen of modified FOLFOX was administered: oxaliplatin, 85mg/m2 for 2 hours; leucovorin, 400mg/m2; and 5-fluorouracil, 2400mg/m2 for 44-46 hours. After HAIC treatment, the catheter or microcatheter, and the sheath were removed.
Study NCT04947826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10 (PD-1 antibody)
Description: PD-1 antibody with proven efficacy in advanced hepatocellular carcinoma
Study NCT04947826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04 (VEGF antibody)
Description: Combination of PD-1 antibody and VEGF antibody might promote the efficacy of HAIC in hepatocellular carcinoma with major portal vein thrombosis.
Study NCT04947826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06308731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine-Based Energy Drink
Description: Energy drink with 200 mg caffeine
Study NCT06308731 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06047379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEO212 Oral Capsule
Description: NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Study NCT06047379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
Study NCT06047379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
Study NCT06047379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
Study NCT06047379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
Study NCT06047379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
Study NCT06047379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
Study NCT06047379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
Study NCT06047379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
Study NCT04822337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
Description: Phase I - Chemotherapy multiple agents systemic Phase II - Maximum Tolerated Dose from Phase I
Study NCT05082233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280 tablets
Description: Treatment group A:SHR7280 tablets ; 300mg BID； Treatment group B:SHR7280 tablets ; 200mg BID； Treatment group C:SHR7280 tablets ; 200mg QD； Treatment group D:SHR7280 tablets ; 400mg BID；
Study NCT05278065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at weekly assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose commercially available e-liquid flavors (tobacco) at each weekly assessment.
Study NCT06431295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FaceScan
Description: Digital visual acuity device built for iOS (iPhone) that conducts an assessment of visual acuity using a combination of integrated light detection and ranging (LiDAR) and voice processing.
Study NCT05940493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Tablet
Study NCT05940493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study NCT04673799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MV088 injection
Description: MV088 injection (60mg) by subcutaneous injection once on the first day
Study NCT04673799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia® injection
Description: Prolia® injection (60mg) by subcutaneous injection once on the first day
Study NCT05304221 — intervention group
Intervention type: OTHER
Intervention: Shamir Resistance Calculator
Description: An on-line calculator which is free and accessible from all devices, which may predict the risk of MDRO infection upon admission, and the risk of nosocomial XDRO infection during the hospitalization.~The calculator contains only parameters that could be extracted bedside, at the first presentation of a septic patient, including the ability to conduct a complete assessment also among patients with reduced consciousness and/or cognition.
Study NCT06374342 — intervention group
Intervention type: DEVICE
Intervention: Bone defect
Description: Bone grafting is a procedure where damaged bones can be repaired or rebuilt using transplanted bone from another source. Sources for transplant bone include the patient (autograft), a cadaver (allograft) or synthetic bone.
Study NCT06374342 — intervention group
Intervention type: DEVICE
Intervention: Spine fusion
Description: Spinal fusion is a surgery procedure that reinforces your back structure and stability by linking two vertebrae together
Study NCT05700916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Polar Lipid-Rich Dairy Powder
Description: Effects of the addition of 6.5 g of milk polar lipids to dairy powder.
Study NCT05700916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dairy Powder
Description: Effects of dairy control powder
Study NCT06374342 — intervention group
Intervention type: DEVICE
Intervention: Cage filling
Description: Intervertebral fusion with cages is a surgical procedure used to stabilize the spine by fusing adjacent vertebrae. The cages, typically made of materials like titanium or plastic, and pre-filled with bone graft substitutes are placed between the vertebrae to maintain the proper spacing and alignment.
Study NCT05161143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: Donafenib: 4-8 weeks after radical surgery,patients will take donafenib, 200mg Bid,at least 6 months.~TACE:4-8 weeks after radical surgery,patients will receive TACE once.
Study NCT05972733 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIL-214
Description: HIL-214